It is an all-human, single cloned antibodies capable of being combined with a moderate and tumour necrosis (TNF)-alpha, which plays a key role in the emergence of multiple self-immunological diseases. In the Rwet Immunisation Section, Adam single resistance is used mainly for the treatment of self-immunised diseases such as rheumatism arthritis (RA), strong straight spinal disease (AS) and silver crumb arthritis (PsA).
Rheumatism (RA)
Rheumatism is a chronic inflammatory disease characterized by arthritis and bone damage. The Adam stand-off by inhibiting TNF-α, mitigating inflammation, reducing arthropod symptoms, improving joint function, and delaying progress in arthropod structural damage. Clinical studies have shown that the treatment of RAs by traditional anti-Rheumatism drugs, such as ATMX, significantly improves the response rates of the American Society of Rheumatism (ACR), ACR50 and ACR70, i.e., to improve joint symptoms and functions. In addition, the stand-alone anti-Adam will significantly improve the quality of health-related life (HR-QOL) and slow down the progress of radiology for structural joint damage.
2. Strong straight spinal disease (AS)
Proximate spinal disease is a chronic inflammatory disease that primarily affects the spinal column and the hip. The Adam stand-up by inhibiting TNF-α, reducing spina syndrome and improving spinal activity and function. Studies have shown that Adam alone treats AS patients effectively to mitigate symptoms, improve their quality of life and, to some extent, prevent the progress of spinal damage.
3. Silver crumb arthritis (PsA)
Silver crumb arthritis is an inflammatory joint disease associated with silver crumb. The Adam single resistance reduces arthritis and skin symptoms by inhibiting TNF-α. Clinical trials have shown that the Adam single resistance has been effective in improving the quality of life of PsA patients with arthritis symptoms and skin changes.
4. Safety and tolerance
The safety and durability of the Adam stand alone is good. Common adverse effects include inoculations, rashes and back pains. In clinical trials, there is no significant difference in the incidence of adverse events compared to placebos in the single anti-Adam. However, when biological agents, such as Adamu, are used, they need to be alert to the risk of infection, especially tuberculosis.
5. Impact of anti-drugs (ADA)
The development of anti-drugs may affect the efficacy and safety of the single anti-drugs in Adam. Studies have shown that the detection of moderate antibodies (NAb) and blood drug concentrations, which are anti-Adam alone, is important for assessing clinical efficacy.
In conclusion, the application of the Adam mono against rheumatizing immunisation has significantly improved the treatment of self-immunised diseases such as RA, AS and PsA, providing new treatment options for patients. However, there is a need to closely monitor patients ‘ responses and potential adverse reactions during treatment to ensure that treatment is safe and effective.
